Compare CVV & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVV | CTXR |
|---|---|---|
| Founded | 1982 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 19.8M |
| IPO Year | N/A | N/A |
| Metric | CVV | CTXR |
|---|---|---|
| Price | $3.34 | $1.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 19.2K | ★ 595.9K |
| Earning Date | 11-10-2025 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,251,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.85 | N/A |
| 52 Week Low | $2.46 | $0.65 |
| 52 Week High | $4.80 | $5.95 |
| Indicator | CVV | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 46.75 |
| Support Level | $3.32 | $1.12 |
| Resistance Level | $3.58 | $1.54 |
| Average True Range (ATR) | 0.21 | 0.14 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 45.82 | 42.04 |
CVD Equipment Corp is engaged in the manufacturing of chemical vapor deposition equipment, customized gas control systems, the manufacturing of process equipment suitable for the synthesis of a variety of one-dimensional nanostructures and nanomaterials and a line of furnaces, all of which are used to produce semiconductors and other electronic components. The company operates through the segments of CVD Equipment, CVD materials, and Stainless Design Concepts, MesoScribe. It generates maximum revenue from the CVD Equipment segment. The CVD Equipment segment manufactures and sells chemical vapor deposition, physical vapor transport, and similar equipment. Company operates in USA, North America, Europe, Middle East and Africa, and Asia-Pacific.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.